JPMorgan Chase & Co. Boosts Illumina (NASDAQ:ILMN) Price Target to $105.00

Illumina (NASDAQ:ILMN) had its price target boosted by JPMorgan Chase & Co. from $100.00 to $105.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential downside of 15.08% from the stock’s current price.

Other research analysts also recently issued reports about the company. Robert W. Baird set a $109.00 price target on Illumina in a report on Friday. Scotiabank downgraded Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target on the stock. in a report on Friday, July 11th. Morgan Stanley upped their price target on Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, August 4th. Cowen reaffirmed a “hold” rating on shares of Illumina in a report on Friday. Finally, UBS Group upped their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Friday. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $115.00.

Illumina Trading Up 24.9%

Shares of NASDAQ:ILMN opened at $123.64 on Friday. The company has a market cap of $19.00 billion, a P/E ratio of 15.65, a PEG ratio of 2.34 and a beta of 1.40. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina has a 1 year low of $68.70 and a 1 year high of $156.66. The stock’s fifty day moving average price is $98.41 and its 200-day moving average price is $92.76.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Sell-side analysts expect that Illumina will post 4.51 earnings per share for the current year.

Institutional Trading of Illumina

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bourgeon Capital Management LLC lifted its stake in shares of Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after acquiring an additional 61,468 shares during the last quarter. GC Wealth Management RIA LLC bought a new stake in shares of Illumina during the 2nd quarter worth approximately $2,289,000. waypoint wealth counsel bought a new stake in shares of Illumina during the 2nd quarter worth approximately $321,000. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Illumina during the 2nd quarter worth approximately $344,000. Finally, OMNI 360 Wealth Inc. bought a new stake in shares of Illumina during the 2nd quarter worth approximately $364,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.